🟢 OTLK is trading 1.8% up today after FDA sets July decision date for Lytenava

OTLK is trading at $1.73 (+1.8%) in pre-market, continuing a rally sparked by the FDA setting a July decision date for its eye drug, Lytenava.

• The FDA recently accepted the resubmitted BLA for Lytenava, a significant milestone that has fueled investor optimism regarding approval prospects.
• Today's price action appears to be a continuation of last week's momentum and positioning, as no new regulatory filings were released this morning.